Recent studies reveal that both sorafenib and erastin enhance the cuproptotic effects of copper ionophore ES and ES-Cu in hepatocellular carcinoma cells by promoting copper-dependent lipoylated protein aggregation, suppressing mitochondrial matrix-related proteases mediated FDX1 protein degradation, and reducing intracellular GSH synthesis [195–198]. Here, FDX1 is linked to hepatocellular carcinoma.